AzTrials
AzTrials

Sickle Cell DiseaseNCT04031521

Near Infrared Spectroscopy in Sickle Cell Pediatric Patients

An observational study of Sickle Cell Disease, run by Children's National Research Institute at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Endothelial dysfunction contributes to vaso-occlusion and acute pain in sickle cell disease. Near infrared spectroscopy (NIRS) technology can measure tissue oxygenation and endothelial function. Read more about this study

Who is it for?
Ages 6 to 21 years
Conditions the study is for
Sickle Cell Disease
What is being tested?
Near infrared spectroscopy
How many people
0 participants
Where
1 siteUnited States
Study dates
26 Jun 2019to 3 Sep 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 21 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: Subjects 6 to 21 years of age of all sickle cell genotypes

Inclusion Criteria for Subjects with Sickle Cell Disease in Pain Crisis:

  1. Age 6 to 21 years old.
  2. Diagnosis of sickle cell anemia: a. Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required).
  3. Acute onset pain crisis in a distribution typical for that subject, onset within the last 7 days and for which hospitalization and parenteral narcotic pain treatment are required.
  4. Ability to provide informed written consent.

Exclusion Criteria for Subjects with Sickle Cell Disease in Pain Crisis:

  1. Pregnancy.
  2. History of non-trivial injury, burns, surgery or skin ulcers on the arms.
  3. Fever or suspected sepsis at time of pain crisis
  4. Administration of any of the following drugs within the last 14 days:
  • Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil)
  • Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan)
  • Nitric oxide donors (nitroglycerin, nitroprusside, nitrates)
  1. Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment.
  2. Diagnosis with any of the following chronic diseases or conditions:
  • History of high blood pressure
  • History of high cholesterol
  • History of diabetes
  • History of chronic kidney disease (serum creatinine must not be greater than 2 mg/dL)
  • History of coronary artery disease or peripheral vascular disease
  1. Received a blood transfusion within 7 days of the study procedure.

Inclusion Criteria for Subjects with Sickle Cell Disease in Steady State:

  1. Age 6-21 years
  2. Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required).
  3. Ability to provide informed written consent.

Exclusion Criteria for Subjects with Sickle Cell Disease in Steady State:

  1. Pregnancy.
  2. History of non-trivial trauma, burns, surgery or skin ulcers on the arms.
  3. Fever or suspected sepsis at time of pain crisis
  4. Experience of an acute pain crisis requiring intravenous (IV) narcotics and hospital admission within the last 14 days.
  5. Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment.
  6. Administration of any of the following drugs within the last 14 days:
  • Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil)
  • Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan)
  • Nitric oxide donors (nitroglycerin, nitroprusside, nitrates)
  1. Diagnosis of any of the following chronic diseases or conditions:
  • History of high blood pressure
  • History of high cholesterol
  • History of diabetes
  • History of chronic kidney disease (serum creatinine must not be greater than 2 mg/dL)
  • History of coronary artery disease or peripheral vascular disease
  1. Received a blood transfusion within 7 days of the study procedure.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Children's National Medical Center

    Washington D.C., District of Columbia, 20010

Other trials in United States

About this study

Official title: Near-infrared Spectroscopy in Sickle Cell Pediatric Patients During Pain Crisis and After Recovery

Endothelial dysfunction contributes to vaso-occlusion and acute pain in sickle cell disease. Near infrared spectroscopy (NIRS) technology can measure tissue oxygenation and endothelial function. The main objective of this study is to study the natural history of tissue muscle oxygenation using NIRS in pediatric sickle cell subjects experiencing acute pain and pediatric sickle cell patients in steady-state.

Being tested
Near infrared spectroscopy
Medical subject headings
Anemia, Sickle Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Near infrared spectroscopyDiagnostic test

    NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.

Study groups in NCT04031521
Study groupRoleWhat they receive
Sickle cell pain crisisNot described
Receives: Diagnostic Test: Near infrared spectroscopy
Sickle cell steady-stateNot described
Receives: Diagnostic Test: Near infrared spectroscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Tissue oxygenation

    Measured: 6 months

Secondary outcomes (1)
  1. Nitric oxide

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jul 2019
  2. Study start26 Jun 2019
  3. Primary completion3 Sep 2023
  4. Study completion3 Sep 2023

Why it stopped: No eligible patient were available/ found

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04031521
Sponsor's protocol ID
Pro00012424
Status last verified
Sep 2023
First submitted
22 Jul 2019
Last updated
14 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Sickle Cell Disease, run by Children's National Research Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 14 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Tissue oxygenation (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in